Simke W Waijer1, Taha Sen1, Clare Arnott2,3, Bruce Neal2, Jos G W Kosterink1,4, Kenneth W Mahaffey5, Chirag R Parikh6, Dick de Zeeuw1, Vlado Perkovic2, Brendon L Neuen2, Steven G Coca7, Michael K Hansen8, Ron T Gansevoort9, Hiddo J L Heerspink10,2. 1. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 2. The George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia. 3. Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. 4. Department of PharmacoTherapy, Epidemiology and Economics, University of Groningen, Groningen, The Netherlands. 5. Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California. 6. Department of Internal Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland. 7. Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. 8. Janssen Research & Development, LLC, Spring House, Pennsylvania. 9. Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 10. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands h.j.lambers.heerspink@umcg.nl.
Abstract
BACKGROUND AND OBJECTIVES: Clinical trials in nephrology are enriched for patients with micro- or macroalbuminuria to enroll patients at risk of kidney failure. However, patients with normoalbuminuria can also progress to kidney failure. TNF receptor-1, TNF receptor-2, and kidney injury marker-1 (KIM-1) are known to be associated with kidney disease progression in patients with micro- or macroalbuminuria. We assessed the value of TNF receptor-1, TNF receptor-2, and KIM-1 as prognostic biomarkers for CKD progression in patients with type 2 diabetes and normoalbuminuria. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: TNF receptor-1, TNF receptor-2, and KIM-1 were measured using immunoassays in plasma samples from patients with type 2 diabetes at high cardiovascular risk participating in the Canagliflozin Cardiovascular Assessment Study trial. We used multivariable adjusted Cox proportional hazards analyses to estimate hazard ratios per doubling of each biomarker for the kidney outcome, stratified the population by the fourth quartile of each biomarker distribution, and assessed the number of events and event rates. RESULTS: In patients with normoalbuminuria (n=2553), 51 kidney outcomes were recorded during a median follow-up of 6.1 (interquartile range, 5.8-6.4) years (event rate, 3.5; 95% confidence interval, 2.6 to 4.6 per 1000 patient-years). Each doubling of baseline TNF receptor-1 (hazard ratio, 4.2; 95% confidence interval, 1.8 to 9.6) and TNF receptor-2 (hazard ratio, 2.3; 95% confidence interval, 1.5 to 3.6) was associated with a higher risk for the kidney outcome. Baseline KIM-1, urinary albumin-creatinine ratio, and eGFR were not associated with kidney outcomes. The event rates in the highest quartile of TNF receptor-1 (≥2992 ng/ml) and TNF receptor-2 (≥11,394 ng/ml) were 5.6 and 7.0 events per 1000 patient-years, respectively, compared with 2.8 and 2.3, respectively, in the lower three quartiles. CONCLUSIONS: TNF receptor-1 and TNF receptor-2 are associated with kidney outcomes in patients with type 2 diabetes and normoalbuminuria. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: CANagliflozin cardioVascular Assessment Study (CANVAS), NCT01032629.
BACKGROUND AND OBJECTIVES: Clinical trials in nephrology are enriched for patients with micro- or macroalbuminuria to enroll patients at risk of kidney failure. However, patients with normoalbuminuria can also progress to kidney failure. TNF receptor-1, TNF receptor-2, and kidney injury marker-1 (KIM-1) are known to be associated with kidney disease progression in patients with micro- or macroalbuminuria. We assessed the value of TNF receptor-1, TNF receptor-2, and KIM-1 as prognostic biomarkers for CKD progression in patients with type 2 diabetes and normoalbuminuria. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: TNF receptor-1, TNF receptor-2, and KIM-1 were measured using immunoassays in plasma samples from patients with type 2 diabetes at high cardiovascular risk participating in the Canagliflozin Cardiovascular Assessment Study trial. We used multivariable adjusted Cox proportional hazards analyses to estimate hazard ratios per doubling of each biomarker for the kidney outcome, stratified the population by the fourth quartile of each biomarker distribution, and assessed the number of events and event rates. RESULTS: In patients with normoalbuminuria (n=2553), 51 kidney outcomes were recorded during a median follow-up of 6.1 (interquartile range, 5.8-6.4) years (event rate, 3.5; 95% confidence interval, 2.6 to 4.6 per 1000 patient-years). Each doubling of baseline TNF receptor-1 (hazard ratio, 4.2; 95% confidence interval, 1.8 to 9.6) and TNF receptor-2 (hazard ratio, 2.3; 95% confidence interval, 1.5 to 3.6) was associated with a higher risk for the kidney outcome. Baseline KIM-1, urinary albumin-creatinine ratio, and eGFR were not associated with kidney outcomes. The event rates in the highest quartile of TNF receptor-1 (≥2992 ng/ml) and TNF receptor-2 (≥11,394 ng/ml) were 5.6 and 7.0 events per 1000 patient-years, respectively, compared with 2.8 and 2.3, respectively, in the lower three quartiles. CONCLUSIONS: TNF receptor-1 and TNF receptor-2 are associated with kidney outcomes in patients with type 2 diabetes and normoalbuminuria. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: CANagliflozin cardioVascular Assessment Study (CANVAS), NCT01032629.
Authors: Tomohito Gohda; Monika A Niewczas; Linda H Ficociello; William H Walker; Jan Skupien; Florencia Rosetti; Xavier Cullere; Amanda C Johnson; Gordon Crabtree; Adam M Smiles; Tanya N Mayadas; James H Warram; Andrzej S Krolewski Journal: J Am Soc Nephrol Date: 2012-01-19 Impact factor: 10.121
Authors: Brendon L Neuen; Toshiaki Ohkuma; Bruce Neal; David R Matthews; Dick de Zeeuw; Kenneth W Mahaffey; Greg Fulcher; Qiang Li; Meg Jardine; Richard Oh; Hiddo L Heerspink; Vlado Perkovic Journal: J Am Soc Nephrol Date: 2019-09-17 Impact factor: 10.121
Authors: Steven G Coca; Girish N Nadkarni; Yuan Huang; Dennis G Moledina; Veena Rao; Jane Zhang; Bart Ferket; Susan T Crowley; Linda F Fried; Chirag R Parikh Journal: J Am Soc Nephrol Date: 2017-05-05 Impact factor: 10.121
Authors: Maryam Afkarian; Leila R Zelnick; Yoshio N Hall; Patrick J Heagerty; Katherine Tuttle; Noel S Weiss; Ian H de Boer Journal: JAMA Date: 2016-08-09 Impact factor: 56.272
Authors: Kathleen F Kerr; Jeremy Roth; Kehao Zhu; Heather Thiessen-Philbrook; Allison Meisner; Francis Perry Wilson; Steven Coca; Chirag R Parikh Journal: Clin Trials Date: 2017-08-10 Impact factor: 2.486
Authors: Venkata S Sabbisetti; Sushrut S Waikar; Daniel J Antoine; Adam Smiles; Chang Wang; Abinaya Ravisankar; Kazumi Ito; Sahil Sharma; Swetha Ramadesikan; Michelle Lee; Rebeccah Briskin; Philip L De Jager; Thanh Thu Ngo; Mark Radlinski; James W Dear; Kevin B Park; Rebecca Betensky; Andrzej S Krolewski; Joseph V Bonventre Journal: J Am Soc Nephrol Date: 2014-06-05 Impact factor: 10.121
Authors: Christina-Alexandra Schulz; Gunnar Engström; Jan Nilsson; Peter Almgren; Marinka Petkovic; Anders Christensson; Peter M Nilsson; Olle Melander; Marju Orho-Melander Journal: Nephrol Dial Transplant Date: 2020-02-01 Impact factor: 5.992